Mode
Text Size
Log in / Sign up

Acupuncture plus sphenopalatine ganglion needling shows higher response rate than loratadine for allergic rhinitisAcupuncture combined with targeted needling may improve allergy symptoms better than standard medication

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider acupuncture-based therapies as a potential non-pharmacologic option for allergic rhinitis, but note the lack of reported safety data.

In a multicenter randomized controlled trial, 260 patients with persistent moderate-to-severe allergic rhinitis were assigned to one of four 8-week treatments: combination therapy (acupuncture 3 sessions/week plus sphenopalatine ganglion needling 1 session/week), pharmacotherapy (loratadine 10 mg/day), acupuncture alone (3 sessions/week), or sphenopalatine ganglion needling alone (1 session/week). The primary outcome was response rate, defined as ≥30% reduction in total nasal symptom score at Week 8.

At Week 8, the response rate was 82.5% for combination therapy, 71.4% for acupuncture alone, 55.7% for sphenopalatine ganglion needling alone, and 45.3% for pharmacotherapy. The relative risk for combination therapy versus pharmacotherapy was 1.90 (95% CI 1.40-2.58, p<0.001), and for acupuncture alone versus pharmacotherapy was 1.61 (95% CI 1.18-2.21, p=0.003). The difference between sphenopalatine ganglion needling alone and pharmacotherapy was not statistically significant. Combination therapy showed the earliest significant improvement, with a 63.5% response rate by Week 2 (p<0.001). Response rates appeared sustained at a 4-week follow-up.

No safety, adverse event, or tolerability data were reported. Key study limitations, funding sources, and conflicts of interest were also not reported. While the results from this RCT suggest combination acupuncture therapy may offer a non-pharmacologic alternative for symptom management, the absence of safety data and unreported limitations necessitate cautious interpretation. Further research with comprehensive safety reporting is needed to confirm these findings.

Researchers conducted a randomized controlled trial to compare different treatments for persistent moderate-to-severe allergic rhinitis, commonly known as hay fever. They studied 260 patients across multiple centers, testing four approaches: standard allergy medication (loratadine), acupuncture alone, a targeted needling technique called sphenopalatine ganglion needling alone, and a combination of acupuncture plus this targeted needling. All treatments were given for 8 weeks, with symptoms tracked for another 4 weeks afterward.

The main finding was that after 8 weeks, more patients in the combination therapy group (82.5%) and the acupuncture-alone group (71.4%) experienced significant symptom relief compared to those on standard medication (45.3%). The combination therapy also showed the fastest improvement, with benefits noticeable by the second week. The targeted needling technique alone did not show a clear advantage over medication in this study.

It's important to be cautious because the study did not report any safety data, side effects, or reasons why patients might have stopped treatment. We don't know if the treatments caused any discomfort or problems. The results are promising for people seeking non-drug options for allergy relief, but they come from a single study without long-term follow-up. Patients should discuss these findings with their doctor rather than changing their treatment based on this research alone.

What this means for you:
Combining acupuncture with a targeted needling technique showed promise for allergy relief in one study, but safety and long-term effects are unknown.

Study Details

Study typeRct
Sample sizen = 260
EvidenceLevel 2
Follow-up1.8 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Although the therapeutic effects of acupuncture and sphenopalatine ganglion (SPG) needling for allergic rhinitis (AR) are well established, evidence for the efficacy of their combination remains limited. METHODS: In this multicenter, randomized, parallel-controlled trial, 260 patients with persistent moderate-to-severe AR were assigned to 8 weeks of pharmacotherapy (MED; loratadine 10 mg/day), acupuncture (ACU; 3 sessions/week), sphenopalatine ganglion needling (SPG-N; 1 session/week), or combination therapy (COM, which received both acupuncture and SPG needling). The primary outcome was the response rate (≥30% reduction in total nasal symptom score [TNSS]) at Week 8. Secondary outcomes included changes in TNSS, total non-nasal symptom score (TNNSS), rhinoconjunctivitis quality of life questionnaire (RQLQ), and visual analogue scale (VAS) scores from baseline to Weeks 2, 4, 8, and the 4-week follow-up. RESULTS: At Week 8, response rates differed significantly among groups (COM: 82.54%; ACU: 71.43%; SPG-N: 55.74%; MED: 45.31%; p < 0.001) and were sustained at the 4-week follow-up. The COM showed the earliest significant improvement at Week 2 (63.49%, p < 0.001). Compared to MED, both COM (relative risk [RR] = 1.90, 95% confidence interval [CI], 1.40-2.58; p < 0.001) and ACU (RR = 1.61, 95% CI, 1.18-2.21; p = 0.003) were associated with significantly higher response rates at Week 8, whereas SPG-N was not (RR = 1.27, 95% CI, 0.90-1.79; p = 0.17). CONCLUSION: This study demonstrated that acupuncture combined with SPG needling provides more rapid, robust, and sustained symptomatic improvement in AR, offering an evidence-based non-pharmacologic alternative for AR management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.